Platform
Designed for adaptability and integration
Platform
Designed for adaptability and integration
Our platform is based on native Outer Membrane Vesicles (nOMVs) derived from Neisseria meningitidis that provide intrinsic innate immune activation. The platform supports flexible multivalent vaccine design: antigens can be displayed on the nOMVs and/or co-administered with them as an adjuvant, enabling tailored immune strategies across multiple routes of administration. This design allows vaccine approaches to be adapted to different
transmission dynamics and public-health needs, while maintaining a consistent underlying technology.
Rather than focusing on a single indication, the AdJane platform incorporates foundational capabilities that can be applied, adapted and integrated across different vaccine strategies and development contexts. This approach supports continuity across programs while allowing components to be adjusted independently as requirements evolve.
The platform can be applied across:
- Viral and bacterial pathogens
- Mono- and multivalent vaccine concepts
- Mucosal and intramuscular routes of administration
Evaluation and application
The platform has been independently evaluated by multiple leading international initiatives. These applications demonstrate the platform’s suitability for reuse across diverse infectious disease scenarios.
Stability and scalability
Our platform has demonstrated long-term stability over five years under standard refrigerated conditions (2–8 °C). This stability supports:
- long-term stockpiling
- simplified global distribution
- deployment in both pandemic response and routine immunization settings
Intellectual property and partnerships
Our platform has been extensively developed and validated and has been described by multiple peer-reviewed publications. AdJane has consolidated this foundation into its fully owned platform and patent portfolio. This provides us with the freedom to operate to develop vaccines across multiple disease areas and allows selective partnering without restrictions or encumbrances. Our platform IP also includes patents covering modulation of innate immune activation, supporting flexibility across both prophylactic and therapeutic vaccine concepts.
Explore our Proprietary Platform
Broad Application
OMV-Vacc is applicable for both bacterial and viral vaccines, administration-route-agnostic, and can be utilized in multivalent vaccine concepts. Our platform ensures broad protection – a key milestone in vaccinology.
Strong and durable immunity
After intramuscular or intranasal administration, OMV-Vacc activates the TLR2 and TLR 4 pathways, inducing a balanced, strong, and durable immune response. ADA induces cellular (Th1), humoral (Th2), and mucosal (Th17) immunity.
Safe and well-tolerated
Clinical Phase I study confirms OMV-Vacc’s excellent safety profile with no adverse effects. The modified Neisseria meningitidis OMV’s are specifically engineered to reduce LPS toxicity while preserving adjuvating properties to trigger a natural immune response.
Scalable, high yield, and excellent stability
Our proprietary GMP manufacturing process is optimized for flexible, high-yield, and consistent production of OMVs, that demonstrate exceptional 5+ years stability under standard cold-chain conditions.